simplywall.stOCT 72 min read$SNY

Sanofi (ENXTPA:SAN) Could Be 2% Undervalued On Its Expanded Regeneron Alliance

Sanofi (SAN) expanded its partnership with Regeneron, committing to four new antibody programs and up to €8b in milestone payments. The stock is trading at €70.61, down 7.41% over 30 days and 14.22% year-to-date. Analysts suggest it may be 2% undervalued, with a fair value of €72.23, but warn of risks related to patent erosion and trial outcomes.

Original reporting

simplywall.st

Published Oct 7, 2026, 4:37 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 8, 2026, 2:15 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Sanofi (ENXTPA:SAN) Could Be 2% Undervalued On Its Expanded Regeneron Alliance — source image — Source · simplywall.st

Decision brief

The 30-second read

$SNYBullishMed

Why it matters

The deal adds a $1 billion upfront payment and up to $8 billion in milestones, potentially lifting Sanofi's revenue outlook.

Market read

First report of a sizable partnership that could reshape Sanofi's immunology pipeline and affect its valuation.

What to watch

Regeneron's own pipeline progress and regulatory approvals remain uncertain

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Sanofi (ENXTPA:SAN) expanded its long‑running alliance with Regeneron, adding four new long‑acting antibody programs.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$SNYBullishHigh confidence

Context

Sanofi announced an expanded Regeneron partnership with up to $8 billion in milestones and a $1 billion upfront fee.

Expected impact

likely upside as investors price in additional pipeline revenue

Evidence & confidence

Large $8 billion milestone potential and fresh cash infusion suggest material revenue upside.

Market effects

Sector

strengthens the broader immunology/biotech sector by highlighting partnership models

Regional

supports European pharma sentiment amid mixed earnings

Global

potentially influences biotech peers evaluating similar collaborations

Counterpoint

What could challenge this read

Milestone payments are contingent; execution risk could limit upside

Key entities

company
Sanofi
French pharmaceutical group expanding its immunology partnership.
company
Regeneron
US biotech partner in the expanded collaboration.

Read at source ← All news

OCT 7

$ABBVHighAI 8/10

Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

Genmab and AbbVie's Epkinly showed promising results in a Phase 3 study, reducing disease progression or death risk by 51% in lymphoma patients. IntraBio was acquired by Shionogi for $2 billion, expanding Aqneursa's approvals. Novartis invested up to $7.8 billion in Abogen Biosciences. Eli Lilly and CSL also announced significant biopharma deals. Sarepta Therapeutics presented positive Elevidys data, with upcoming catalysts for its treatments.

biospace.com3 min

OCT 6

$LLYLow

Factbox-Global healthcare companies invest billions to boost US presence

Global healthcare companies, including Pfizer, Eli Lilly, and AstraZeneca, are investing billions in US manufacturing and research. Pfizer plans $70B, Eli Lilly $27B, and AstraZeneca $50B. Investments aim to mitigate supply-chain risks and tariff impacts, with some companies reporting minimal 2025 tariff effects.

finance.yahoo.com3 min

OCT 6

$SNYMed

Vaccine seasonality to weigh on Sanofi in third quarter

Sanofi expects a 2% sales boost from favorable currency effects in Q3 2026, but anticipates a 10-15% decline in vaccine sales due to seasonality. The decline is attributed to delayed influenza vaccine deliveries and increased competition for its RSV vaccine, Beyfortus. The company's full-year vaccine sales are expected to decline slightly.

marketscreener.com2 min

OCT 5

$SNYMedAI 8/10

More evidence shows dupilumab boosts growth trajectory for kids with eczema

A study presented at the European Academy of Dermatology and Venerology Congress found that children with atopic dermatitis who were underweight saw significant gains in body weight and BMI after 16 weeks of dupilumab treatment, with the greatest gains observed in children aged 2 to 5 years and underweight girls. Dupilumab is developed by Sanofi and Regeneron. The findings suggest that dupilumab may address growth deficits in underweight children with atopic dermatitis, according to researchers.

healio.com2 min

OCT 4

$SNYHighAI 9/10

Regeneron and Sanofi expand antibody alliance in potential $8 billion deal

Regeneron and Sanofi expanded their 20-year antibody partnership, adding four new antibodies. Regeneron will receive $1B upfront, with up to $7B more in milestones. The companies will jointly develop and commercialize the antibodies, with Regeneron leading R&D and Sanofi handling global commercial efforts. Dupixent's profit-sharing remains unchanged.

indianpharmapost.com2 min

OCT 3

$NVSHighAI 9/10

Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals

Novartis agreed to pay up to $7.8B for Abogen's RNA drug ABO2203, targeting autoimmune diseases. Sanofi will co-develop four inflammation drugs with Regeneron for up to $7.8B. Novo Nordisk licensed Hengrui's obesity pill HRS-1596 for up to $2.6B. AstraZeneca invested $2B in Summit Therapeutics' cancer drug. Merck acquired SciBrunch's cancer pill SPR2015 for up to $2.13B.

tradingview.com2 min